# OnCo record brigimadlin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/brigimadlin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "brigimadlin" ;
  schema:name "Brigimadlin"@en ;
  schema:alternateName "BI 907828"@en, "BI-907828"@en ;
  schema:description "Brigimadlin is a tablet that frees the p53 'guardian' protein from MDM2, the protein that liposarcomas make in excess to keep p53 switched off. It is being compared with doxorubicin as first treatment for dedifferentiated liposarcoma in a phase 2/3 trial."@en ;
  schema:url <https://onco.cc/drugs/brigimadlin/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:status "phase-3" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Oral MDM2-p53 antagonist" ;
  onco:related <https://onco.cc/drugs/doxorubicin/> ;
  onco:cancers <https://onco.cc/cancers/liposarcoma/> ;
  onco:targets <https://onco.cc/targets/mdm2/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> .